Media

Onxeo Final Data from Mechanistic Livatag® Study Show Preferential Affinity for Liver, Support Use as Advanced HCC Treatment

Cerenis Therapeutics announces the publication of an initiation of coverage report by PORTZAMPARC, within the framework of the share’s market coverage

Nordic Nanovector ASA: Betalutin® continues to show promising efficacy and increasing Duration of Response (DoR)

WILSON THERAPEUTICS PRESENTS DATA ON DECUPRATE™ (WTX101) FROM ONGOING PHASE 2 STUDY AT THE INTERNATIONAL LIVER CONGRESS™ 2016

NORDIC NANOVECTOR ENTERS COLLABORATION WITH PAUL SCHERRER INSTITUTE TO DEVELOP NEW ANTIBODY RADIONUCLIDE CONJUGATES FOR TREATING LEUKAEMIAS

Strongbridge Biopharma plc Announces Presentation at 15th Annual Needham Healthcare Conference

Altimmune Expands Clinical Development Team

Strongbridge Biopharma plc Announces Presentation of COR-003 Data at the Endocrine Society’s 2016 Annual Conference

Nexstim Plc Appoints John Liedtky as VP of Commercialisation, General Manager US and announces the retirement of John Hardin